相似文献
1
[The consensus of the diagnosis of monoclonal gammopathies of clinical significance in China (2022)].
Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):631-635. doi: 10.3760/cma.j.issn.0253-2727.2022.08.003.
2
Screening panels for detection of monoclonal gammopathies: confidence intervals.
Clin Chem. 2010 Apr;56(4):677-9; author reply 679-80. doi: 10.1373/clinchem.2009.139097. Epub 2010 Jan 28.
3
What about (MG)US? Towards tailored testing in monoclonal gammopathies.
Haematologica. 2023 Jun 1;108(6):1455-1457. doi: 10.3324/haematol.2022.282271.
4
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant.
Blood. 2012 Nov 22;120(22):4292-5. doi: 10.1182/blood-2012-07-445304. Epub 2012 Oct 9.
5
When a Monoclonal Gammopathy Is Not Multiple Myeloma.
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-10. doi: 10.1200/EDBK_349643.
6
[Skin disorders associated with monoclonal gammopathies].
Ned Tijdschr Geneeskd. 2014;158:A6717.
7
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
Lancet Haematol. 2022 May;9(5):e340-e349. doi: 10.1016/S2352-3026(22)00069-2. Epub 2022 Mar 25.
8
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
J Clin Oncol. 2023 Jun 1;41(16):3019-3031. doi: 10.1200/JCO.22.01916. Epub 2023 Mar 17.
9
Screening for and diagnosis of monoclonal gammopathy.
J Clin Pathol. 2023 Nov;76(11):727-733. doi: 10.1136/jcp-2023-208774. Epub 2023 Aug 21.
10
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Hematol Oncol Clin North Am. 2014 Oct;28(5):775-90. doi: 10.1016/j.hoc.2014.06.005. Epub 2014 Jul 22.
本文引用的文献
1
Treatment and outcomes of POEMS syndrome: changes in the past 20 years.
Blood Cancer J. 2021 Aug 14;11(8):145. doi: 10.1038/s41408-021-00540-1.
2
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631.
3
Whole-genome sequencing suggests a role of MIF in the pathophysiology of TEMPI syndrome.
Blood Adv. 2021 Jun 22;5(12):2563-2568. doi: 10.1182/bloodadvances.2020003783.
4
Monoclonal Gammopathy of Renal Significance.
N Engl J Med. 2021 May 20;384(20):1931-1941. doi: 10.1056/NEJMra1810907.
5
CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies.
Blood. 2020 Nov 19;136(21):2428-2436. doi: 10.1182/blood.2020007092.
6
Rituximab-containing therapy for cold agglutinin disease: a retrospective study of 16 patients.
Sci Rep. 2020 Jul 29;10(1):12694. doi: 10.1038/s41598-020-69465-2.
7
Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients.
Ann Hematol. 2020 Aug;99(8):1735-1740. doi: 10.1007/s00277-020-04123-1. Epub 2020 Jun 13.
8
What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?
Leukemia. 2019 Apr;33(4):1023-1029. doi: 10.1038/s41375-019-0391-2. Epub 2019 Jan 30.
9
Bortezomib-based chemotherapy can improve renal and tubular functions in patients with light chain-associated Fanconi syndrome.
Ann Hematol. 2019 May;98(5):1095-1100. doi: 10.1007/s00277-018-3572-6. Epub 2018 Dec 4.
10
Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance.
Curr Opin Neurol. 2017 Oct;30(5):457-463. doi: 10.1097/WCO.0000000000000477.
Zotero 插件